Olympus continues to grow endoscope business
The Japanese medtech firm’s main business area remains on the growth track in its first quarter of 2022/2023, even when adjusting for a big impact from currency effects of a strong US dollar.
by christian bundgaard, translated by daniel pedersen
Olympus has kept its endoscope business on track in the three months of April, May, and June, making up the Japanese medtech company’s first quarter report for fiscal 2022/2023.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ambu downgrades, will cut costs
For subscribers
Boston Scientific exceeds most expectations in Q2
For subscribers
